anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A three-year, longitudinal, triangulation research method was applied. First Year (Phase I): A preliminary HBA exercise program, including hard copy descriptions and DVD demonstrations of each exercise, was mailed to the 16 experts in the Delphi advisory panel for their critique and evaluation. First Year (Phase II): A quasi-experimental, one-group, pretest-posttest design was used to pilot-test the feasibility of the HBA exercise program on a group of 31 community-dwelling older adults in a community care station. Second Year: A cluster randomized controlled trial was used to test the effects of a six-month, instructor-led HBA exercise program on the functional fitness (cardiovascular-respiratory function, body flexibility, muscle strength, and muscle endurance) of the community-dwelling older adults. Through the use of convenience sampling strategy, eight community care stations with 232 older adults in Kaohsiung were recruited and randomly assigned based on their community care stations to a HBA experimental group or a wait-list control group. Participants in the experimental group received the HBA exercise program led by trained and certified instructors, three times per week, 40 minutes per practice for six months; participants in the wait-list control group continued with their regular daily activities. One pre-test and two post-tests, three months apart, were conducted. Third Year: Using the same method as in the second year, participants from the second year continued practicing the HBA exercise program, but guided by a DVD, for another six months. The feasibility, compliance, and effectiveness of the DVD-led HBA exercise program on the community-dwelling older adults were tested, and another two post-tests, three months apart, were conducted on the same outcome measurements as in the second year.
In a placebo-controlled clinical trial of patients with RA, no difference was detected in anti- pneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. The clinical significance of this is unknown. Patients on IDACIO may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving adalimumab products. 

It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating IDACIO therapy. Patients on IDACIO may receive concurrent vaccinations, except for live vaccines. 

The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live- attenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].
FIELD: chemical industry, more particularly manufacture of varnishes, cosmetic and plastic materials. SUBSTANCE: pigment comprises inorganic matrix coated with one or plurality reflecting layers which are thin transparent or semitransparent layers of metals or oxides thereof. Matrix is formed of precursor with silicon dioxide, silicate, boron oxide, borate, aluminium oxide, aluminate or mixture thereof. Matrix comprises modifiers, network-forming agents, soluble or insoluble colorants. Reflecting layer includes Ag, Au, Pa, Pt, Al, Cr, Cu, chromium oxide, iron oxide, titanium dioxide or mixture thereof. Liquid film of matrix material precursor is applied onto endless cape, dried and treated with acid. The resulting matrix is separated from endless cape and coated with reflecting layers. Laminar pigments have intensive luster, high covering power or transparency, are prepared by simple and economic method and have wide color spectrum. EFFECT: improved properties of the coloring laminar pigment. 30 cl, 24 ex, 2 dwg
Composition based on, at least, a cellulose derivative that comprises ester groups of cellulose, being part of them formiato groups, which can form fibers or films with the following properties. A) degree of substitution gs of the cellulose are formiato groups at least 2 percent and degree of polymerization gp of the cellulose, higher than 150 and less than 1,500. B) t> 20 and mi> 1,000; being the tenacity and my initial module of the fiber in cn/tex. C) is constituted by superposed layers around the axle of the filament, variing the optical direction and recristalization in each lay into a pseudoperiodic way throughout the axis. D) delta n> 0.03; being deltan the birthfringency. Dissolution procedure to obtain the composition. (Machine-translation by Google Translate, not legally binding)
The invention discloses a biphenyl compound as well as a preparation method and an application thereof. The molecular formula of the biphenyl compound is C22H26O8, and the compound is named as neglignanD and has a structural formula shown in the specification. The preparation method comprises the following steps: performing extracting, organic solvent extracting, silicagel column chromatography, high performance liquid chromatography separation on the branches, leaves and fruit of dry schisandra chinensis which belong to macrophanerophytes and are used as raw materials. The application is the application of the biphenyl compound in preparing an anti-cancer drug. According to cytotoxic activity test, the neglignanD has good cytotoxic activity for cell strains such as NB4, A549, SHSY5Y, PC3 and MCF7. The compound disclosed by the invention is simple in structure, good in activity and good in application prospect and can be used as the pilot compound of the anti-cancer drug.
The present invention provides a human insulin gene which completes site-specific mutation on C peptide amino acid, which is recombined and reconstructed by adding a first intron. The recombined sequence is characterized in that basic groups in the positions from No. 669 to No. 674 are codons AAG and codons CGC; the basic groups in the positions from No. 1536 to No. 1538 are the codons GGA; the basic groups in the positions from No. 1542 to No. 1544 are the codons CGG; and the basic groups in the positions from No. 305 to No. 483 are the first enlarged intron. The human insulin recombinant gene is used as a medicament for treating diabetes to be applied, and can be used as raw materials of medicaments for treating diabetes in clinics or being directly prepared into various preparation types for treating diabetes in clinics.
ANCA-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis. All forms may involve different organ systems, yet kidney and lung involvement are common and fatal in many cases. Here, we aimed to determine the predictive value of pulmonary disease manifestation and individual CT findings in AAV patients. Available CT scans and clinical information on mortality, renal outcomes, occurrence of relapses and damage scores were analysed retrospectively from a tertiary rheumatology center in Germany. We included a total of 94 AAV patients (49 with GPA, 41 with MPA). Forty-four patients had lung involvement with available CT scans, 70.5% of which with GPA and 72.7% with renal involvement. Nodule formation and cavities were more frequent among GPA patients, whereas ground-glass opacities (GGO), ILD and pleural effusion were observed predominantly in MPA patients. Over a median follow-up of 37 months, GPA patients had a slightly higher overall mortality, whereas end-stage kidney failure rates were significantly increased in MPA patients. Relapse frequencies were comparable between both entities. The presence of GGO and pleural effusion were associated with higher relapse rates, whereas nodules were negatively correlated with relapses. Notably, RTX-treated patients had less infections as compared to individuals under different therapies. Our data demonstrate the outstanding importance of characteristic CT patterns in AAV diagnosis assessment. Especially certain CT patterns including GGO and pleura effusion may help to identify patients who are at higher risk for relapsing disease.
Pediatric: The pharmacokinetics of gemifloxacin in pediatric subjects have not been studied.

Geriatric: In adult subjects, the pharmacokinetics of gemifloxacin are not affected by age.

Gender: There are no significant differences between gemifloxacin pharmacokinetics in males and females when differences in body weight are taken into account. Population pharmacokinetic studies indicated that following administration of 320 mg gemifloxacin, AUC values were approximately 10% higher in healthy female patients compared to males. Males and females had mean AUC values of 7.98 μg•hr/mL (range, 3.21 – 42.71 μg•hr/mL) and 8.80 μg•hr/mL (range, 3.33 – 47.73 μg•hr/mL), respectively. No gemifloxacin dosage adjustment based on gender is necessary.

Hepatic Insufficiency: The pharmacokinetics following a single 320 mg dose of gemifloxacin were studied in patients with mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) liver disease. There was a mean increase in AUC (0-inf) of 34% and a mean increase in Cmax of 25% in these patients with hepatic impairment compared to healthy volunteers.

The pharmacokinetics of a single 320 mg dose of gemifloxacin were also studied in patients with severe hepatic impairment (Child-Pugh Class C). There was a mean increase in AUC (0-inf) of 45% and a mean increase in Cmax of 41% in these subjects with hepatic impairment compared to healthy volunteers.

These average pharmacokinetic increases are not considered to be clinically significant. There was no significant change in plasma elimination half-life in the mild, moderate or severe hepatic impairment patients. No dosage adjustment is recommended in patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment. (See  DOSAGE AND ADMINISTRATION  .)

Renal Insufficiency: Results from population pharmacokinetic and clinical pharmacology studies with repeated 320 mg doses indicate the clearance of gemifloxacin is reduced and the plasma elimination is prolonged, leading to an average increase in AUC values of approximately 70% in patients with renal insufficiency. In the pharmacokinetic studies, gemifloxacin Cmax was not significantly altered in subjects with renal insufficiency. Dose adjustment in patients with creatinine clearance >40 mL/min is not required. Modification of the dosage is recommended for patients with creatinine clearance ≤40 mL/min. (See  DOSAGE AND ADMINISTRATION .)

Hemodialysis removes approximately 20 to 30% of an oral dose of gemifloxacin from plasma.
PURPOSE:In a toothpaste composition containing powdery base to elute >= bivalent metallic ion, the titled composition having improved shape retention and dispersibility in the mouth, causing no solid-liquid separation for a long period, using both a polyacrylic acid of crosslinking type and xanthan gum as a binder. CONSTITUTION:A toothpaste composition containing powdery base such as potassium secondary phosphate, etc. to elute >= bivalent metallic ion as a brushing agent is blended with a polyacrylic acid of crosslinking type and/or its salt and xanthan gum. For example, Carbopol 940, Reogik 250H, etc. may be cited as the polyacrylic acid of crosslinking type or its salt. Especially the acrylic acid of crosslinking type or its salt having 10,000-80,000cps viscosity of 1wt% aqueous solution is preferable. A blending ratio of the polyacrylic acid of crosslinking type to xanthan gum is preferably 3:1-1:3 by weight, and total blended amounts of the two components are preferably 0.5-2.5wt% based on the total amounts of the composition.
The invention relates to the field of biology, genetics and medicine. In particular, the invention relates to novel methods for the detection, characterisation and/or treatment (or management) of neurodegenerative pathologies. The invention also relates to methods for the identification or screening of compounds active in the aforementioned pathologies. The invention further relates to the compounds, genes, cells, plasmids or compositions which are used to carry out the above-mentioned methods. The invention is based on the identification of the role of phosphodiesterase 4B, the peripheral benzodiazepine receptor (PBR) and GABA(A)-type GABA receptors in neurodegenerative pathologies. In addition, the invention outlines the use of same as therapeutic, diagnostic or experimental markers or targets for said disorders.
Epigenetic alterations such as dysregulation of miRNAs have been reported to play important roles in interactions between genetic and environmental factors. In this study, we tested the hypothesis that induction of lung inflammation by inhaled allergens triggers a sex-specific miRNA regulation that is dependent on chromosome complement and hormonal milieu. We challenged the four core genotypes (FCGs) model through intranasal sensitization with a house dust mite (HDM) solution (or PBS as a control) for 5 wk. The FCG model allows four combinations of gonads and sex chromosomes: 1) XX mice with ovaries (XXF), 2) XY mice with testes (XYM), 3) XX mice with testes (XXM), and 4) XY mice with ovaries (XYF). Following the challenge (n = 5-7/group), we assessed the expression of 84 inflammatory miRNAs in lung tissue using a PCR array and cytokine levels in bronchoalveolar lavage fluid (BAL) by a multiplex protein assay (n = 4-7 animals/group). Our results showed higher levels of the chemokine KC (an Il-8 homolog) and IL-7 in BAL from XYF mice challenged with HDM. In addition, IL-17A was significantly higher in BAL from both XXF and XYF mice. A three-way interaction among treatment, gonads, and sex chromosome revealed 60 of 64 miRNAs that differed in expression depending on genotype; XXF, XXM, XYF, and XYM mice had 45, 32, 4, and 52 differentially expressed miRNAs, respectively. Regulatory networks of miRNAs identified in this study were implicated in pathways associated with asthma. Female gonadal hormonal effects may alter miRNA expression and contribute to the higher susceptibility of females to asthma.NEW & NOTEWORTHY miRNAs play important roles in regulating gene and environmental interactions. However, their role in mediating sex differences in allergic responses and lung diseases has not been elucidated. Our study used a targeted omics approach to characterize the contributions of gonadal hormones and chromosomal components to lung responses to an allergen challenge. Our results point to the influence of sex hormones in miRNA expression and proinflammatory markers in allergic airway inflammation.
Healing following rotator cuff repair (RCR) remains a significant clinical challenge, and repair failure rates of 20-30% continue to be reported. To date limited attention has been directed toward understanding how intrinsic mechanistic factors may contribute to variable healing rates following RCR. The objective of this proposal is to quantify the variability of the humeral head bone marrow in patients undergoing RCR and test the prognostic significance of the local concentration of connective tissue progenitors (CTPs) for tendon healing. Our approach will be to enroll 50 patients undergoing RCR. At the time of RCR, 8 ml of bone marrow will be aspirated from the humeral head for quantitative progenitor cell assays. A core biopsy at the tendon repair footprint will be collected for histologic analysis of bone marrow composition. Tendon healing will be assessed by MRI (Sugaya score) at 6 months follow-up, the timeframe in which majority of re-tears occur The variation of bone marrow characteristics among patients will be described (Aim 1) and their correlation with rotator cuff tendon healing will be investigated (Aim 2). The proposal seeks to shift the investigational paradigm to intrinsic patient biologic factors, a fundamental and under-investigated realm of potential prognostic factors of RCR healing. Demonstrating that humeral head characteristics associate with re-tear after RCR will support future work to develop tools to screen patient bone marrow for characteristics predictive of RCR success or failure and advance novel methods that promote local enrichment or transplantation of progenitor cells to augment RCR.
PROBLEM TO BE SOLVED: To provide a pain-relieving spray ultra-ion solution, which is a magnetic liquid electro-magnetized by a titanium oxide photocatalyst and a method in which a titanium oxide liquid and a diluent are sprayed in the form of mist to resolve cellular pain and skin troubles.SOLUTION: According to the present invention, there is provided a pain-relieving spray ultra-ion solution, which can be used to (1) spray for cellular pain or skin trouble; (2) apply for cellular pain or skin trouble; (3) paste for cellular pain or skin trouble; (4) immerse for cellular pain, or skin trouble, cloth/chemical fiber, etc.; (5) compound for dispensing/formulation; and (6) spray, apply, paste, roll, and immerse for troubles, such as itching. In the solution, (7) titanium oxide photocatalyst is specified as a food additive and (8) sterilization in the mouth is done with strong bactericidal power of titanium oxide. The solution can be also used for (9) spraying on the body to remove aging odor generated with advancing age; and is (10) effective for circulation disorder or economy class syndrome caused by spending a night sleeping in a car in an earthquake disaster. Furthermore, (11) production of the composition can be done easily on a small scale. There is an advantage that the production can be inexpensive. It is a production method that allows the production to be performed safely and securely.
Follow-up visits are always organized in the same way. A consultation with a gastropediatrician will take place, with assessment of symptoms (PEESS score) and quality of life (PedsQL module for eosinophilic esophagitis and PedsQL 4.0 Generic Core Scales). Then, if treatment needs to be introduced or changed, a digestive endoscopy with biopsies will be carried out at 3 months to determine whether the patient is in remission or not. Depending on the results, the patient may be advised to adapt or maintain the current treatment.
<P>PROBLEM TO BE SOLVED: To provide humanized monoclonal antibodies which recognize human IL-10 and modulate its activity with regard to autoimmune disorders.  <P>SOLUTION: Compositions and methods disclosed herein relate generally to interleukin-10 (IL-10) specific antibodies and uses thereof. More specifically, the invention relates to the composition of humanized IL-10 specific antibody in the modulation of IL-10 activity (particularly in autoimmune disorders and pathogen-induced immunopathology), and using methods for such antibodies. The humanized monoclonal antibodies recognize human IL-10, particularly to autoimmune disorders, and modulate its activity. The humanized antibodies provide an alternative therapy choice without the toxicity and non-specificity associated with current treatments.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Treatment strategies for preventing liver fibrosis have not yet been established. Letrozole, widely used for breast cancer, has recently been reported to suppress liver fibrosis in murine models. Therefore, we aimed to validate the suppressive effects of letrozole on liver fibrosis in the clinical setting. From 2006 to 2020, 23 consecutive patients who received continuous letrozole treatment for 24 months or more and had a liver fibrosis marker FIB-4 index of ≥ 2.30, were included. Forty-three patients who underwent anastrozole treatment for 24 months or more and had a liver fibrosis marker FIB-4 index of ≥ 2.30, were also included as controls. The Fisher exact, chi-square, unpaired Student t, and paired Student t test were used to analyze the data. The patient characteristics were similar between the letrozole- and anastrozole-treated patient groups. Among the letrozole-treated patients, the mean FIB-4 index tended to decline during letrozole treatment; a significant decrease was observed at 18 and 24 months compared with the baseline values (p = 0.044 and p = 0.013). In addition, the mean aspartate aminotransferase-to-platelet ratio index (APRI) decreased during letrozole treatment; the values at 18 and 24 months were significantly lower than those at baseline (p = 0.024 and p = 0.026). In contrast, among anastrozole-treated patients, the mean FIB-4 index and APRI did not change during anastrozole treatment. When changes in the FIB-4 index were further examined in a limited number of patients with a FIB-4 index ≥ 2.67, a significant reduction in the FIB-4 index at 24 months compared with baseline was also observed in letrozole-treated patients (p = 0.023), but not in anastrozole-treated patients. In conclusion, our findings support a possible suppressive effect of letrozole on liver fibrosis in the clinical setting. Further studies are required to better understand the pharmacological effects of letrozole.
Devices, systems and methods are disclosed which relate to remotely monitoring the health of an individual. The individual wears a health monitoring device, with an attached strap, capable of sensing characteristics of the individual. These characteristics may include voice level and tone, movements, blood pressure, temperature, etc. The device allows individuals to constantly monitor their health without having to physically visit a doctor or other health care professional. Wireless communication, for instance with an Internet Protocol Television (IPTV) set-top box, allows measurements to be made and evaluated by a computerized healthcare service provider. For a more accurate evaluation, measurements are sent over the INTERNET to a service. The device communicates with services in order to diagnose the individual based upon the characteristics.
The control group will consist of 20 participants (n=20) who will receive local care for the ulcer. The patient will undergo a surgical debridement procedure for the ulcer to be in its optimal condition (Visit 1). Subsequently, the patient will receive the application of a conventional dressing with Hydrogel, dry gauze, and a crepe bandage. The patient will be instructed to change the dressing at least once a day.
The invention relates to the technical field of vaccine adjuvant, in particular relates to a compound oil adjuvant. The compound oil adjuvant comprises three ingredients, namely white oil, oleyl alcohol polyoxyethylene ether and polyoxyethylene ether stearate. The white oil accounts for 80-95%, the oleyl alcohol polyoxyethylene ether accounts for 1-10%, and the polyoxyethylene ether stearate accounts for 1-10%. Molecular weight of the oleyl alcohol polyoxyethylene ether is 400-600, and the molecular weight the polyoxyethylene ether stearate is 400-600. The preparation method of the compound oil adjuvant disclosed by the invention comprises the steps of respectively weighing the white oil, the oleyl alcohol polyoxyethylene ether and the polyoxyethylene ether stearate in proportion of a prescription and mixing to be uniform. The invention also discloses an application of the compound oil adjuvant in preparation of an animal vaccine. The invention successfully solves the problem that a W/O/W type emulsion vaccine is difficult to prepare, the prepared emulsion vaccine is convenient for injection and also has good immunogenicity, and stability of the prepared emulsion vaccine is better than that of the W/O/W type emulsion vaccine prepared by ISA206.